Amgen prepares for pricing battle over PCSK9-inhibitor Repatha; Otsuka loses Abilify lawsuit; healthcare and pharma marketers will boost spending on digital advertising in 2015
The Medicare enrollment period that just concluded differed in one major way from those of years past: Marketers found, both to their delight and chagrin, that the pool of Medicare eligibles now includes many individuals perfectly comfortable with digital communications. Tom Reid shares a few thoughts on what marketers have learned—or, in some cases, should've learned
Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.
The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate
The updated app now tracks everyday health metrics including weight, activity and glucose levels.
Multiple marketing channels offer an effective way to ensure that meaningful relationships can be developed with prospects and when done right can increase revenue by more than 10% while reducing costs by 25%, if not both
While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions
The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.
The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.
Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.